Navigation Links
ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand
Date:12/12/2011

ADDISON, Texas, Dec. 12, 2011 /PRNewswire/ -- ULURU Inc. (NYSE AMEX: ULU), announced today that it has extended the territory of the previously announced European license for Altrazeal®, with a subsidiary of Melmed Holdings AG, to include Australia and New Zealand.

Extending the European territory to include Australia and New Zealand is a logical progression as there is a common registration process and the marketing strategy and tactics will be essentially the same in both territories. European key opinion leaders are well regarded in Australia and New Zealand and will be utilized in the product launch and the subsequent marketing programs. Also, Australia is considered a world leader in wound management, with the largest wound research program in the world, the Wound Management Innovation Cooperation Research Center ("WMICRC") being headquartered at the Queensland University of Technology. A component of the Australian launch plan will be an active collaboration with this research center, which is focused on improving wound healing and quality-of-life while providing cost-effective wound care that lessens the burden on the health care system.

The Australian State Governments strategic priorities are characterized by the twin pillars of clinical effectiveness and benchmarked operating cost efficiency.  Hospitals are seeking to achieve clinical endpoints, the restoration of patient health and wellbeing, as quickly and cost effectively as possible so patients are returned to their communities or moved to appropriate after hospital care, reducing the burden on state funding. Therefore, a product such as Altrazeal® that can accelerate patient restoration while reducing health care costs aligns directly with government strategic imperatives and best practice.

Commenting on the extension of the License Agreement, Kerry P. Gray, President and CE
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
2. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
4. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
5. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Announces Conference Call
8. ULURU Inc. Provides Altrazeal® Clinical Update
9. ULURU Inc. Reports Third Quarter 2010 Financial Results
10. ULURU Inc. to Raise $500,000 in Registered Direct Offering
11. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... ActivBiotics, Inc. today,announced the results of its ... rifalazil in the treatment of intermittent claudication,associated ... demonstrated,that treatment for two months with the ... significant improvement in walking distance,claudication onset times, ...
... Scientific Sessions ... 2007 in Orlando, Florida, ... ) today announced the successful completion,of its Phase 2b trial ... vaccine being,developed to treat nicotine addiction and prevent smoking relapse. ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
(Date:7/13/2014)... Nature Genetics identifies a novel genetic and ... esophagitis (EoE), opening up potential new therapeutic strategies ... , EoE is a chronic inflammatory disorder of ... hypersensitivity to certain foods and an over-accumulation in ... (part of the body,s immune system). EoE can ...
(Date:7/13/2014)... North American water storage systems market is estimated to grow ... at a CAGR of 21.0%, from 2013 to 2018. The ... in North America. The U.S. is experiencing high growth on ... and collection, and the increased spending on modernization and upgradation ... rate in Canada, and is rising at a rapid pace ...
(Date:7/13/2014)... July 13, 2014 According to ... and Computing Market by Component (processor, GPU, DSP, ... MDA, Medical), and Geography - Forecast and Analysis ... Mobile Processing & Computing Market is expected to ... CAGR of 20.75% from 2014 to 2020. , ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its ... beautiful. Recently, the company has announced its new selection ... more, all these outfits are available at discounted prices ... the supplier is now offering similar discounts for many ... has many other designs for sale, including flower girl ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2
... Gardner HealthDay Reporter , TUESDAY, Aug. 31 (HealthDay ... a strong policy statement directed toward pediatricians, parents and the ... are getting about sex from television, the Internet and other ... Media , was published online Aug. 30 and in the ...
... the National Institutes of Health and University of Chicago ... mice reduces the severity of skin and soft-tissue damage ... Staphylococcus aureus infections in the United States. By ... found they could greatly reduce the damaging effects of ...
... lawsuit about gay marriage, the talk at some point turns ... parents? Will their children whether adopted, conceived with the ... relationship adjust, adapt and succeed in a world dominated ... giving them, and come dressed in anecdotes and colored by ...
... (August 31, 2010) A new study ... Massachusetts General Hospital (MGH) suggests that S-Adenosyl Methionine ... effective, relatively well-tolerated, adjunctive treatment for adults with ... their treatment with antidepressant medication. This first-of-its-kind ...
... vaccination of healthcare personnel is a professional and ... regarding vaccination should not be tolerated, according to ... for Healthcare Epidemiology of America (SHEA). The paper, ... Healthcare Epidemiology journal and endorsed by the ...
... OAK BROOK, Ill. A study of triathletes published in ... reveals that the heart adapts to triathlon training by working ... first study using MRI to investigate effects of triathlon training ... associate professor at the University of Erlangen-Nuremberg in Erlangen, Germany. ...
Cached Medicine News:Health News:U.S. Pediatricians Decry Media's Portrayal of Sex 2Health News:U.S. Pediatricians Decry Media's Portrayal of Sex 3Health News:Treatment for S. aureus skin infection works in mouse model 2Health News:Treatment for S. aureus skin infection works in mouse model 3Health News:Children raised by gay couples show good progress through school 2Health News:Children raised by gay couples show good progress through school 3Health News:Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders 2Health News:Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders 3Health News:Nation's leading ID experts call for mandatory flu vaccine for all health-care personnel 2Health News:Combining resistance and endurance training best for heart health 2
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
Medicine Products: